Is ABBV a very good inventory to purchase? We got here throughout a bullish thesis on AbbVie Inc. on X.com by @MoneyShow. On this article, we’ll summarize the bulls’ thesis on ABBV. AbbVie Inc.’s share was buying and selling at $227.68 as of March eleventh. ABBV’s trailing and ahead P/E have been 96.07 and 15.65 respectively in response to Yahoo Finance.
Copyright: mikkolem / 123RF Inventory Picture
AbbVie Inc., a research-based biopharmaceutical firm, engages within the analysis and improvement, manufacturing, commercializing, and sale of medicines and therapies worldwide. ABBV is navigating the post-Humira period with a diversified and rising drug portfolio, efficiently transitioning from reliance on its former blockbuster. Humira, as soon as the world’s bestselling drug with over $20 billion in annual gross sales, noticed its U.S. patent expire in 2023 and misplaced safety abroad earlier, inflicting AbbVie’s income to say no briefly.
The corporate, nevertheless, anticipated this eventuality and has launched a collection of recent therapies in immunology and oncology which are already offsetting Humira’s decline. Its immunology medicine, Skyrizi and Rinvoq, now generate mixed gross sales of $6.9 billion, on monitor to surpass Humira’s peak efficiency, with steering projecting $31 billion in 2027 and $40 billion by 2029. Past these, AbbVie’s pipeline is in depth, with 20 medicine in section III trials and over 50 in earlier improvement, concentrating on high-demand indications equivalent to blood cancers and Parkinson’s illness. This positions the corporate for sustained development and important future income streams.
Regardless of previous headwinds from patent expirations, AbbVie’s shares have rebounded, rising over 20% in 2025, reflecting the market’s recognition of its profitable transition and sturdy outlook. The corporate additionally combines development with sturdy revenue, providing a $6.92 annual dividend, representing a 3.1% yield, and sustaining a 53-year historical past of annual dividend will increase, averaging 12.5% development over the previous decade. With its de-risked income trajectory, increasing pipeline, and dependable money circulation, AbbVie presents a pretty funding alternative, mixing revenue stability with development potential, making the inventory a compelling purchase for traders looking for each yield and capital appreciation.
Beforehand, we coated a bullish thesis on AbbVie Inc. (ABBV) by Magnus Ofstad in Could 2025, which highlighted sturdy Q1 efficiency, Skyrizi and Rinvoq offsetting Humira’s decline, and breakthroughs in oncology with Elahere. ABBV’s inventory worth has appreciated by roughly 14.7% since our protection. @MoneyShow shares an analogous view however emphasizes AbbVie’s post-Humira transition, increasing pipeline, and long-term dividend development as core funding drivers.